



Screening, Early Detection and Prevention of Hepato-Pancreato-Biliary (HPB) Cancers

Guest Editor:

Dr. Zaed Z.R. Hamady

1. Human Development & Health,
University of Southampton,
Southampton SO16 6YD, UK
2. University Hospital
Southampton NHS Foundation
Trust, Southampton SO16 6YD,
UK

Deadline for manuscript
submissions:

1 April 2025

Message from the Guest Editor

Dear Colleagues,

Much of the morbidity and mortality caused by human cancer is related to late diagnosis, where surgical and pharmacologic therapies are less effective. Most late-stage pancreatic and liver cancers follow a palliative treatment pathway. Therefore, facilitating early diagnosis is an important strategy to achieve longer survival (WHO, guide to cancer early diagnosis, 2017).

In addition, there are measures which can prevent or reduce the chance of HPB cancer in at-risk populations. These measures have highlighted some pharmacological agents, vaccines and supplements that may be recommended for public use.

The growing understanding of genomic, epigenomic and machine learning pathways has led to a pronounced diversification of diagnostic options, and thus to a significant improvement in the early diagnosis of cancer.

In this Special Issue, innovative screening, early detection and prevention technologies will be highlighted from the perspective of basic, translational and clinical pathway research, with the overall goal of improving them and identifying new potential targets.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)